These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 16219622)
1. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622 [TBL] [Abstract][Full Text] [Related]
2. Ifosfamide or trofosfamide in patients with intraocular lymphoma. Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202 [TBL] [Abstract][Full Text] [Related]
3. New insights into the clinical pharmacokinetics of trofosfamide. Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306 [TBL] [Abstract][Full Text] [Related]
4. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans. Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712 [TBL] [Abstract][Full Text] [Related]
6. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite. Boos J; Küpker F; Blaschke G; Jürgens H Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592 [TBL] [Abstract][Full Text] [Related]
7. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528 [TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Boddy AV; English M; Pearson AD; Idle JR; Skinner R Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549 [TBL] [Abstract][Full Text] [Related]
11. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies. Kiewe P; Neumann M; Wagner T; Seyfert S; Albrecht H; Thiel E; Korfel A Cancer Chemother Pharmacol; 2011 Jan; 67(1):27-33. PubMed ID: 20182727 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ifosfamide and some metabolites in children. Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448 [TBL] [Abstract][Full Text] [Related]
13. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies. Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071 [TBL] [Abstract][Full Text] [Related]
14. Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature. Jahnke K; Bechrakis NE; Coupland SE; Schmittel A; Foerster MH; Fischer L; Thiel E; Korfel A Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):771-6. PubMed ID: 15349786 [TBL] [Abstract][Full Text] [Related]
15. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Lokiec F Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799 [TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
19. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610 [TBL] [Abstract][Full Text] [Related]
20. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Lokiec F; Santoni J; Weill S; Tubiana-Hulin M Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]